Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients.
Adult
Aged
B-Lymphocytes
/ immunology
Carcinoma, Non-Small-Cell Lung
/ immunology
Humans
Lung Neoplasms
/ immunology
Lymphocyte Activation
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Middle Aged
Retrospective Studies
T-Lymphocytes, Regulatory
/ immunology
Transcriptome
Tumor Microenvironment
/ immunology
B cell
immune checkpoint
immune microenvironment
lung cancer
regulatory T cell
tertiary lymphoid structure
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
11
2020
accepted:
09
02
2021
entrez:
25
3
2021
pubmed:
26
3
2021
medline:
21
9
2021
Statut:
epublish
Résumé
The presence of tertiary lymphoid structures (TLS) in the tumor microenvironment is associated with better clinical outcome in many cancers. In non-small cell lung cancer (NSCLC), we have previously showed that a high density of B cells within TLS (TLS-B cells) is positively correlated with tumor antigen-specific antibody responses and increased intratumor CD4
Identifiants
pubmed: 33763071
doi: 10.3389/fimmu.2021.626776
pmc: PMC7983944
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
626776Informations de copyright
Copyright © 2021 Germain, Devi-Marulkar, Knockaert, Biton, Kaplon, Letaïef, Goc, Seguin-Givelet, Gossot, Girard, Validire, Lefèvre, Damotte, Alifano, Lemoine, Steele, Teillaud, Hammond and Dieu-Nosjean.
Déclaration de conflit d'intérêts
DG and AS-G received fees from Medtronic company for presentations not in relation with this topic. DG is consultant for an instrument manufacturer (Delacroix Chevalier). KS and SH are full-time employees of AstraZeneca. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2015 Feb 23;6:67
pubmed: 25755654
J Clin Invest. 2013 Jul;123(7):2873-92
pubmed: 23778140
Immunity. 2015 Jun 16;42(6):1100-15
pubmed: 26084025
J Immunol. 2008 Apr 15;180(8):5222-34
pubmed: 18390703
Immunity. 2002 Feb;16(2):311-23
pubmed: 11869690
J Clin Oncol. 2008 Sep 20;26(27):4410-7
pubmed: 18802153
J Exp Med. 2010 Apr 12;207(4):689-97
pubmed: 20308362
J Exp Med. 2015 Nov 16;212(12):2115-31
pubmed: 26481684
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Immunity. 2015 Mar 17;42(3):471-83
pubmed: 25786177
Cancer Res. 2014 Feb 1;74(3):705-15
pubmed: 24366885
Nat Rev Immunol. 2013 Apr;13(4):227-42
pubmed: 23470321
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Mucosal Immunol. 2012 Sep;5(5):544-54
pubmed: 22549742
J Hematol Oncol. 2018 Mar 15;11(1):39
pubmed: 29544515
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Cancer Res. 2012 Nov 1;72(21):5473-82
pubmed: 22962270
Oncoimmunology. 2018 Jan 29;7(5):e1423184
pubmed: 29721382
Elife. 2014 Nov 19;3:
pubmed: 25407678
Cancer Cell. 2018 Mar 12;33(3):463-479.e10
pubmed: 29455927
Oncoimmunology. 2015 Jun 1;4(12):e1051922
pubmed: 26587322
J Natl Cancer Inst. 1994 Jun 1;86(11):829-35
pubmed: 8182763
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
Eur Respir J. 2001 Dec;18(6):1059-68
pubmed: 11829087
PLoS One. 2013;8(3):e58006
pubmed: 23526963
J Clin Invest. 2014 May;124(5):2204-18
pubmed: 24691446
Immunity. 2008 Aug 15;29(2):261-71
pubmed: 18656387
Eur J Cancer. 2016 Nov;67:1-10
pubmed: 27591414
J Exp Med. 2010 Apr 12;207(4):681-8
pubmed: 20308365
Nat Rev Immunol. 2003 Aug;3(8):609-20
pubmed: 12974476
Oncoimmunology. 2017 Aug 30;6(12):e1371896
pubmed: 29209572
Methods Mol Biol. 2018;1845:205-222
pubmed: 30141015
J Immunol. 2000 Feb 15;164(4):2160-9
pubmed: 10657670
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
J Immunol. 2004 Nov 15;173(10):5944-51
pubmed: 15528328
Nat Med. 1997 Jun;3(6):682-5
pubmed: 9176498
Chest. 2009 Jul;136(1):260-271
pubmed: 19584208
Immunity. 2015 Sep 15;43(3):579-90
pubmed: 26341400
EMBO J. 2007 Jul 11;26(13):3191-202
pubmed: 17568779
Nat Med. 2004 Sep;10(9):927-34
pubmed: 15311275
J Immunol. 1995 Aug 1;155(3):1151-64
pubmed: 7636184
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
Front Immunol. 2016 Oct 03;7:407
pubmed: 27752258
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
J Exp Med. 2010 Sep 27;207(10):2187-94
pubmed: 20819927
Trends Immunol. 2012 Jun;33(6):297-305
pubmed: 22622061